Oncofertility Expands as Under-50 Cancer Diagnoses Rise 22% and More Patients Preserve Fertility
Updated
Updated · The Boston Globe · Aug 11
Oncofertility Expands as Under-50 Cancer Diagnoses Rise 22% and More Patients Preserve Fertility
3 articles · Updated · The Boston Globe · Aug 11
Summary
Cancer and fertility specialists are increasingly helping younger patients freeze eggs, embryos, sperm, or ovarian tissue before treatment, giving more survivors a path to biological children.
Rising need is driving that shift: U.S. cancer diagnoses in people under 50 climbed about 22% from 2000 to 2023, while breast cancer in women under 50 is increasing roughly 1.4% a year.
Demand has surged alongside better reproductive tools. Boston IVF’s New England cancer consultations rose from 19 in 2015 to 183 in 2025, and Brigham and Women’s oncology fertility referrals jumped 49% from 2022 to 2025.
Access still hinges on speed, awareness and cost. Some clinics fast-track patients within 48 hours, but embryo freezing can cost up to $20,000 without insurance, and storage fees can keep adding debt.
New research is widening options: Dana-Farber found women with early hormone-sensitive breast cancer could pause hormone therapy for up to 2 years to pursue pregnancy, with 69% having at least one baby after five years.
Could the revolutionary protocols allowing young cancer survivors to freeze embryos inadvertently expose them to long-term risks we haven't yet discovered?
When saving a life costs your life savings, how will society fix the devastating financial toxicity of modern oncofertility treatments?
If medical science can safely pause cancer treatment for pregnancy, why are thousands still denied this chance by hidden insurance loopholes?